Search hospitals
>
California
>
Los Angeles
Jonsson Comprehensive Cancer Center, UCLA
Claim this profile
Los Angeles, California 90095
Global Leader in Breast Cancer
Global Leader in Brain Tumor
Conducts research for Prostate Cancer
Conducts research for Leukemia
Conducts research for Lung Cancer
725 reported clinical trials
43 medical researchers
Summary
Jonsson Comprehensive Cancer Center, UCLA is a medical facility located in Los Angeles, California. This center is recognized for care of Breast Cancer, Brain Tumor, Prostate Cancer, Leukemia, Lung Cancer and other specialties. Jonsson Comprehensive Cancer Center, UCLA is involved with conducting 725 clinical trials across 516 conditions. There are 43 research doctors associated with this hospital, such as Zev A. Wainberg, William A. May, Theodore Moore, MD, and Sara Hurvitz, MD.
Area of expertise
Breast Cancer
Jonsson Comprehensive Cancer Center, UCLA has run 76 trials for Breast Cancer. Some of their research focus areas include:
Brain Tumor
Jonsson Comprehensive Cancer Center, UCLA has run 76 trials for Brain Tumor. Some of their research focus areas include:
Top PIs
Zev A. Wainberg
UCLA
3 years of reported clinical research
William A. May
Mattel Children's Hospital UCLA
8 years of reported clinical research
Theodore Moore, MD
Mattel Children's Hospital UCLA
8 years of reported clinical research
Sara Hurvitz, MD
UCLA Medical Center / David Geffen School of Medicine
4 years of reported clinical research
Clinical Trials running at Jonsson Comprehensive Cancer Center, UCLA
Prostate Cancer
Breast Cancer
Bladder Cancer
Kidney Cancer
Rectal Cancer
Cancer
Breast cancer
Bladder Carcinoma
Testicular cancer
Brain Tumor
Apalutamide + Targeted Radiation
for Prostate Cancer
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting
2 awards
Phase 3
Apalutamide + Hormone and Radiation Therapies
for Prostate Cancer
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.
Recruiting
2 awards
Phase 3
177Lu-PSMA-617
for Prostate Cancer
This phase II trial tests how well re-treatment with 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic), that continues to grow or spread after the surgical removal of the testes or medical treatment to block androgen production (castration-resistant), and that has shown a favorable response to initial treatment with 177Lu-PSMA-617. 177Lu-PSMA-617 is a radioactive drug. It binds to a protein called prostate specific membrane antigen (PSMA), which is expressed by some types of prostate tumor cells. When 177Lu-PSMA-617 binds to PSMA-expressing tumor cells, it delivers radiation to the cells, which may kill them. Re-treatment with 177Lu-PSMA-617 in patients who had a favorable response to initial 177Lu-PSMA-617 treatment may improve survival outcomes and disease response in patients with metastatic castration-resistant prostate cancer.
Recruiting
1 award
Phase 2
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Jonsson Comprehensive Cancer Center, UCLA?
Jonsson Comprehensive Cancer Center, UCLA is a medical facility located in Los Angeles, California. This center is recognized for care of Breast Cancer, Brain Tumor, Prostate Cancer, Leukemia, Lung Cancer and other specialties. Jonsson Comprehensive Cancer Center, UCLA is involved with conducting 725 clinical trials across 516 conditions. There are 43 research doctors associated with this hospital, such as Zev A. Wainberg, William A. May, Theodore Moore, MD, and Sara Hurvitz, MD.
Where is Jonsson Comprehensive Cancer Center, UCLA located?
**UCLA Jonsson Comprehensive Cancer Center** - **Address:** 10833 Le Conte Ave, Los Angeles, CA 90024 - **Directions:** From the east, take the 10 (Santa Monica Freeway) east to 405 (San Diego Freeway) north. Exit on Wilshire Blvd east to reach the center.
Who should I call to ask about financial aid or insurance network?
Jonsson Comprehensive Cancer Center, UCLA Hospital Financial Assistance and Insurance Departments: **Financial Assistance:** - Julia Leavitt, Financial Counselor: [email protected] - UCLA Health Financial Assistance Program: 310-825-8021 (Monday through Friday, 8:30 am to 4:00 pm) **Insurance:** - Jay Russell, Insurance Officer: jrussell@ashe.ucla.edu - Adrian Martinez, Insurance Officer: amartinez@ashe.ucla.edu
What insurance does Jonsson Comprehensive Cancer Center, UCLA accept?
The UCLA Jonsson Comprehensive Cancer Center accepts most health insurance plans, including Medicare, and most HMO and PPO insurance, billing directly for covered services. It's advised to confirm your coverage with your benefits coordinator or health insurance company, as accepted plans may change.
What awards or recognition has Jonsson Comprehensive Cancer Center, UCLA received?
The Jonsson Comprehensive Cancer Center at UCLA is designated as a Comprehensive Cancer Center by the National Cancer Institute (NCI), highlighting its excellence in research, education, and patient care. It is renowned for groundbreaking discoveries, including the development of Herceptin for breast cancer and Keytruda for metastatic melanoma. The Center is also committed to community outreach, health disparities research, and the development of supportive cancer care and survivorship programs.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.